We are live on ! Find out more
CAPR icon

Capricor Therapeutics

33 hedge funds and large institutions have $4.32M invested in Capricor Therapeutics in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

623% more capital invested

Capital invested by funds: $598K → $4.32M (+$3.73M)

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

83% more funds holding

Funds holding: 1833 (+15)

0.99% more ownership

Funds ownership: 5.61%6.6% (+0.99%)

9% less call options, than puts

Call options by funds: $249K | Put options by funds: $274K

Holders
33
Holders Change
+15
Holders Change %
+83.33%
% of All Funds
0.68%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
9
Reduced
2
Closed
3
Calls
$249K
Puts
$274K
Net Calls
-$25K
Net Calls Change
-$25K

CAPR Hedge Fund Activity: Q2 2020 in Review

33 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2020, worth a combined $4.32M — up 623% from $598K a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CAPR positions and 3 closed out — a net gain of 15 holders — while 9 added to existing stakes and 2 trimmed.

The largest buyer was Northern Trust, opening a new position worth an estimated $647K. The largest seller was Armistice Capital, exiting entirely with an estimated $322K sold.

  • 33 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2020, up from 18 in Q1 2020.
  • Funds reported $4.32M of Capricor Therapeutics stock for Q2 2020, up 623% quarter-over-quarter.
  • 18 funds opened new Capricor Therapeutics positions in Q2 2020 and 3 closed out, a net change of +15 holders.
  • The largest Capricor Therapeutics buyer in Q2 2020 was Northern Trust, an estimated $647K added.
  • The largest Capricor Therapeutics seller in Q2 2020 was Armistice Capital, an estimated $322K sold.

Based on aggregated 13F filings for Q2 2020.